BNT-221
- Generic Name
- BNT-221
A Clinical Study of the Safety and Activity of the Investigational Cell Therapy NEO-PTC-01 in Patients With Advanced Melanoma
Phase 1
Terminated
- Conditions
- Unresectable MelanomaMetastatic Melanoma
- Interventions
- First Posted Date
- 2020-11-12
- Last Posted Date
- 2025-04-06
- Lead Sponsor
- BioNTech US Inc.
- Target Recruit Count
- 22
- Registration Number
- NCT04625205
- Locations
- 🇧🇪
Universitair Ziekenhuis Brussel, Brussel, Belgium
🇳🇱Netherlands Cancer Institute - Antoni van Leeuwenhoek, Amsterdam, Netherlands
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath